华润双鹤(600062.SH)：阿法骨化醇软胶囊获得药品注册证

Core Viewpoint - China Resources Double Crane Pharmaceutical (华润双鹤) announced that its wholly-owned subsidiary, Beijing Wanhui Double Crane Pharmaceutical Co., Ltd. (万辉双鹤), has received the Drug Registration Certificate for Alfacalcidol Soft Capsules from the National Medical Products Administration (国家药品监督管理局) [1] Group 1: Product Information - Alfacalcidol Soft Capsules are indicated for the treatment of calcium metabolism disorders caused by insufficient endogenous 1,25-dihydroxyvitamin D3 production [1] - The drug is applicable for various conditions, including renal osteodystrophy, postoperative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, as an adjunct therapy for tertiary hyperparathyroidism, vitamin D-resistant rickets or osteomalacia, vitamin D-dependent rickets, neonatal hypocalcemia or rickets, malabsorption of calcium, osteoporosis, malabsorption-related and nutritional rickets, and osteomalacia [1]